GLP-1s are not going anywhere pharma manufacturers continue to evolve their GLP-1/GIP product offerings (e.g., Eli Lillys Zepbound is the newest on the market), and the number of addressable indications is increasing (e.g., recent clinical evidence that may merit further FDA approval of GLP-1s for cardio-metabolic, nephrological and neurological indications)
Data published from Voys supervised programme, covering over 125,000 members, showed 24% average weight loss at 12 months , compared to 16% in controlled clinical trials of the same medication
This usually fades within a few hours
If you are already on a stable semaglutide dose with manageable GI symptoms, creatine is usually well-tolerated
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
Given the potential adverse consequences of sarcopenic obesity there is a need to educate healthcare professionals about the risks and to incorporate lifestyle interventions to prevent gains in fat and optimise muscle mass following GLP-1 RA cessation
